Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
McKesson
Moodys
Boehringer Ingelheim
Colorcon

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Claims for Patent: 8,778,923

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,778,923
Title:GLP-1 receptor modulators
Abstract: The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of GLP-1 receptor on their own, or with receptor ligands including GLP-1 peptides GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where \"\" represents either or both the R and S form of the compound): ##STR00001## where A, B, C, Y.sub.1, Y.sub.2, Z, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, W.sub.1, n, p and q are as defined herein.
Inventor(s): Boehm; Marcus F. (San Diego, CA), Martinborough; Esther (San Diego, CA), Moorjani; Manisha (San Diego, CA), Tamiya; Junko (Carlsbad, CA), Huang; Liming (San Diego, CA), Yeager; Adam R. (La Mesa, CA), Brahmachary; Enugurthi (San Diego, CA), Fowler; Thomas (Melton Mowbray, GB), Novak; Andrew (Nottingham, GB), Meghani; Premji (Leicestershire, GB), Knaggs; Michael (Burton-on-Trent, GB)
Assignee: Receptos, Inc. (San Diego, CA)
Application Number:13/712,624
Patent Claims:1. A compound having the structure of Formula I-R or I-S or a pharmaceutically acceptable isomer, enantiomer, racemate, salt, ester, prodrug, hydrate or solvate thereof: ##STR00527## wherein A is a 5-, 6- or 7-membered heteroaryl having one, two or three heteroatoms where each such heteroatom is independently selected from O, N, and S, and where any ring atom of such heteroaryl may be optionally substituted with one or more of R.sub.4; B is heterocyclyl or heterocyclylalkyl; C is aryl or arylalkyl; Y.sub.1 and Y.sub.2 are both null; Z is --C(O)--; each R.sub.1 is independently H or C.sub.1-4 alkyl; R.sub.2 is --O--R.sub.8, --N(R.sub.1)--SO.sub.2--R.sub.8, --NR.sub.41R.sub.42, --N(R.sub.1)--(CR.sub.aR.sub.b).sub.m--COOH, --N(R.sub.1)--(CR.sub.aR.sub.b).sub.m--CO--N(R.sub.1)-heterocyclyl, --N(R.sub.1)--(CR.sub.aR.sub.b).sub.m--CO--N(R.sub.1)(R.sub.7), or --N(R.sub.1)-heterocyclyl, wherein R.sub.2 is not --OH or --NH.sub.2; each R.sub.3 and R.sub.4 is independently H, halo, alkyl, alkyl substituted with R.sub.31, alkoxy, haloalkyl, perhaloalkyl, haloalkoxy, perhaloalkoxy, aryl, heterocyclyl, --OH, --OR.sub.8, --CN, --NO.sub.2, --NR.sub.1R.sub.8, --C(O)R.sub.8, --C(O)NR.sub.1R.sub.8, --NR.sub.1C(O)R.sub.8, --SR.sub.8, --S(O)R.sub.8, --S(O).sub.2R.sub.8, --OS(O).sub.2R.sub.8, --S(O).sub.2NR.sub.1R.sub.8, --NR.sub.1S(O).sub.2R.sub.8, --(CR.sub.aR.sub.b).sub.mNR.sub.1R.sub.8, --(CR.sub.aR.sub.b).sub.mO(CR.sub.aR.sub.b).sub.mR.sub.8, --(CR.sub.aR.sub.b).sub.mNR.sub.1(CR.sub.aR.sub.b).sub.mR.sub.8 or --(CR.sub.aR.sub.b).sub.mNR.sub.1(CR.sub.aR.sub.b).sub.mCOOH; or any two R.sub.3 or R.sub.4 groups on the same carbon atom taken together form oxo; each R.sub.31 is independently H, halo, hydroxyl, --NR.sub.41R.sub.42, or alkoxy; each R.sub.40 is independently H or alkyl; each R.sub.41 and R.sub.42 is independently R.sub.40 or --(CH.sub.2).sub.n--COO--R.sub.40, --C(O)--R.sub.40, aryl, heteroaryl, or two taken together with the N atom to which they are attached can form a 3- to 7-membered heterocyclyl; W.sub.1 is null or -L.sub.1-(CR.sub.aR.sub.b).sub.m-L.sub.1-R.sub.6; each L.sub.1 is independently, from the proximal to distal end of the structure of Formula I-R or I-S, null, --C(O)O--, --S(O.sub.2)--, --S--, --N(R.sub.1)--C(O)--N(R.sub.1)--, --N(R.sub.1)--C(O)--O--, --(O)-- or --S(O.sub.2)--NR.sub.1--; each R.sub.a and R.sub.b is independently H, alkyl, alkoxy, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, any of which alkyl, alkoxy, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl may be optionally (singly or multiply) substituted with R.sub.7, or --(CH.sub.2).sub.mC(O)OR.sub.40, --(CH.sub.2).sub.mOR.sub.40, --(CH.sub.2).sub.mSR.sub.40, --(CH.sub.2).sub.mNR.sub.41R.sub.42, --(CH.sub.2).sub.mC(O)NR.sub.41R.sub.42; or any two R.sub.a and R.sub.b taken together with the carbon to which they are attached form a cycloalkyl or heterocyclyl; or R.sub.1 and any one of R.sub.a or R.sub.b taken together form heterocyclyl; R.sub.5 is R.sub.7, --(CH.sub.2).sub.m-L.sub.2-(CH.sub.2).sub.m--R.sub.7, or -(-L.sub.3-(CR.sub.aR.sub.b).sub.r-).sub.s-L.sub.3-R.sub.7; R.sub.6 is H, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocycloalkyl, any of which may be optionally singly or multiply substituted with R.sub.7 or --(CH.sub.2).sub.m-L.sub.2-(CH.sub.2).sub.m--R.sub.7; R.sub.7 is H, halo, alkyl, haloalkyl, perhaloalkyl, alkoxy, --OH, --OR.sub.8, --CN, --NR.sub.1R.sub.8, --(CR.sub.aR.sub.b).sub.mO(CR.sub.aR.sub.b).sub.mR.sub.8, --NR.sub.1(CR.sub.aR.sub.b).sub.mR.sub.8, --C(O)R.sub.8, --NR.sub.1(CR.sub.aR.sub.b).sub.mCOOH, --NR.sub.1C(O)R.sub.8, --C(O)NR.sub.1R.sub.8, --SR.sub.8, --S(O)R.sub.8, --S(O).sub.2R.sub.8, --S(O).sub.2NR.sub.1R.sub.8, --NR.sub.1S(O).sub.2R.sub.8; or a ring moiety selected from cycloalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, where such ring moiety is optionally singly or multiply substituted with halo, --OH, --CN, alkyl, alkoxy, haloalkyl or perhaloalkyl; each R.sub.8 is independently H, alkyl, cycloalkyl or aryl; L.sub.2 is independently, from the proximal to distal end of the structure of Formula I-R or I-S, null, --O--, --OC(O)--, --NR.sub.1--, --C(O)NR.sub.1--, --N(R.sub.1)--C(O)--, --S(O.sub.2)--, --C(O)-- or --S(O.sub.2)--N(R.sub.1)--; each L.sub.3 is independently null, --O--, or --N(R.sub.1)-- each m is independently 0, 1, 2, 3, 4, 5 or 6; each n is independently 0 or 1 or 2; p is 0, 1, 2 or 3; q is 0, 1, 2 or 3; each r is independently 2, 3, or 4; and each s is independently 1, 2, 3, or 4.

2. The compound of claim 1 wherein A is a 5- or 6-membered heteroaryl group.

3. The compound of claim 2 wherein the compound has the following structure: ##STR00528## ##STR00529## ##STR00530## ##STR00531##

4. The compound of claim 1 wherein C is aryl.

5. The compound of claim 4 wherein the compound has the following structure: ##STR00532##

6. The compound of claim 1 wherein B is heterocyclyl.

7. The compound of claim 1 wherein the compound has the following structure: ##STR00533## ##STR00534## ##STR00535##

8. A pharmaceutical composition comprising a compound of claim 1 together with at least one pharmaceutically acceptable carrier, diluent or excipient.

9. A pharmaceutical combination comprising the compound of claim 1 and a second medicament.

10. The pharmaceutical combination of claim 9 wherein the second medicament is an agonist or modulator for glucagon receptor, GIP receptor, GLP-2 receptor, or PTH receptor, or glucagon-like peptide 1 (GLP-1) receptor.

11. The pharmaceutical combination of claim 9 wherein the second medicament is exenatide, liraglutide, taspoglutide, albiglutide, or lixisenatide.

12. The pharmaceutical combination of claim 9 wherein the second medicament is a DPPIV inhibitor.

Details for Patent 8,778,923

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Glaxosmithkline Llc TANZEUM albiglutide INJECTABLE;INJECTION 125431 001 2014-04-15   Start Trial Receptos, Inc. (San Diego, CA) 2039-02-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Express Scripts
McKesson
Dow
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.